ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

SUMM Summit Therapeutics Plc

20.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.50 18.00 23.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Summit Therapeutics plc Summit Highlights Importance Of Innovation In Fight Against Antibiotic Resistance During Antibiotics ...

12/11/2018 12:00pm

UK Regulatory


 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Summit Highlights Importance of Innovation in Fight Against Antibiotic 
Resistance During Antibiotics Awareness Week 
 
 
   -- Preclinical Data on New Mechanism Antibiotic SMT-571 for the Treatment of 
      Gonorrhoea are the Focus of an Oral Presentation at the SCI/RSC Symposium 
      on Antimicrobial Drug Discovery 
 
 
   Oxford, UK, and Cambridge, MA, US, 12 November 2018 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism 
antibiotic innovation, marks the start of Antibiotics Awareness Week 
today by highlighting the importance of innovation in the discovery and 
development of new antibiotics. 
 
   "As bacteria render existing classes of antibiotics less and less 
effective, infectious diseases are an ever-increasing threat to human 
life. To counter this threat, Summit Therapeutics is one of the few 
companies developing genuinely innovative, new mechanism antibiotics," 
said Dr David Roblin, President of R&D of Summit. "We believe our 
Discuva Platform can support the discovery of multiple new mechanism 
antibiotics against the most serious bacterial threats. Through our 
research, we have already found several new vulnerabilities in a range 
of bacteria, providing us with potential new antibiotic targets to which 
bacteria have not been previously exposed. Our goal is to use this 
information to continually develop new mechanism antibiotics to become 
new standards of care." 
 
   Within Summit's current pipeline of new mechanism antibiotics is 
SMT-571, which is the focus of an oral presentation at the 2(nd) SCI/RSC 
Symposium on Antimicrobial Drug Discovery taking place 12-13 November in 
London, UK. SMT-571 is a selective antibiotic being developed 
specifically for the treatment of gonorrhoea. Current treatment 
guidelines for gonorrhoea recommend combination therapy of two 
broad-spectrum antibiotics, ceftriaxone and azithromycin. Resistance to 
azithromycin and reduced susceptibility to ceftriaxone are becoming 
global issues in the treatment of gonorrhoea and there are no approved 
gonorrhoea treatments to replace these antibiotics. In addition, 
ceftriaxone's over-use for gonorrhoea could create further health 
burdens by promoting resistance of other life-threatening bacteria, for 
which ceftriaxone is currently an antibiotic of choice, such as in the 
treatment of meningitis. 
 
   If approved, Summit believes SMT-571 has the potential to be used as a 
front-line treatment, which could help to promote antibiotic stewardship 
by allowing broad-spectrum antibiotics to be reserved for more 
appropriate infections. Data being presented at the SCI/RSC Symposium 
highlight SMT-571's new mechanism of action, which has resulted in 
potency against multiple different clinical gonorrhoea isolates in 
preclinical studies, including multi-drug resistant strains and those 
showing reduced susceptibility to ceftriaxone. In addition, SMT-571 
appears to have characteristics which are suitable for oral 
administration and co-administration with antibiotics for other sexually 
transmitted diseases. The development of SMT-571 is supported, in part, 
by an award from CARB-X through the end of a Phase 1 clinical trial. 
 
   Added Dr Roblin, "By targeting specific infections or pathogens, we 
believe we can develop the optimal drug for the patient and healthcare 
provider and improve clinical outcomes. This antibiotic stewardship 
approach promotes the right drug for the right pathogen upfront and 
preserves broad-spectrum antibiotics for severe, systemic infections." 
 
   Other new mechanism antibiotic programmes in Summit's pipeline include 
ridinilazole, a Phase 3-ready precision antibiotic for C. difficile 
infection, and a discovery-stage ESKAPE program. The bacteria addressed 
by Summit's programmes are all on priority lists from the World Health 
Organization ('WHO') and the US Centres for Disease Control and 
Prevention ('CDC') because of the urgent need for new antibiotics 
against them. 
 
   Antibiotics Awareness Week is a global event recognised worldwide by the 
WHO, in the US by the CDC, in Europe by the European Centre for Disease 
Prevention and Control, in Canada by the National Collaborating Centre 
for Infectious Diseases and by Australia by the Australian Commission on 
Safety and Quality Health Care. The initiative seeks to raise awareness 
about antibiotic resistance and steps everyone can take to help avoid 
further spread of antibiotic resistance. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for C. 
difficile infection and gonorrhoea and are using our proprietary Discuva 
Platform to expand our pipeline. For more information, visit 
www.summitplc.com and follow us on Twitter @summitplc. 
 
   Research reported in this press release is supported by the Cooperative 
Agreement Number IDSEP160030 from ASPR/BARDA and by an award from 
Wellcome Trust, as administrated by CARB-X. The content is solely the 
responsibility of the authors and does not necessarily represent the 
official views of the Department of Health and Human Services Office of 
the Assistant Secretary for Preparedness and Response, other funders, or 
CARB-X. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)     Tel:                  44 (0)1235 443 951 
Erik Ostrowski / Michelle Avery (US office)                         +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                  Tel:                 +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                  Tel:                 +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer, Corporate 
 Finance 
 Tom Salvesen, Corporate Broking 
 
Panmure Gordon (Joint Broker)              Tel:                 +44 (0)20 7886 2500 
Freddy Crossley, Corporate Finance 
 James Stearns, Corporate Broking 
 
MSL Group (US)                             Tel:                     +1 781 684 6557 
                                                         mailto:summit@mslgroup.com 
Jon Siegal                                                      summit@mslgroup.com 
                                                  --------------------------------- 
 
Consilium Strategic Communications (UK)    Tel:                 +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart / Jessica          mailto:summit@consilium-comms.com 
 Hodgson /                                         summit@consilium-comms.com 
                                                  --------------------------------- 
Lindsey Neville 
 
 
   Summit Forward-looking Statements 
 
   Any statements in this press release about the Company's future 
expectations, plans and prospects, including but not limited to, 
statements about the potential benefits of the CARB-X award, including 
whether the option segments will be exercised, the clinical and 
preclinical development of the Company's product candidates, the 
therapeutic potential of the Company's product candidates, the potential 
commercialisation of the Company's product candidates, the sufficiency 
of the Company's cash resources, the timing of initiation, completion 
and availability of data from clinical trials, the potential submission 
of applications for marketing approvals and other statements containing 
the words "anticipate," "believe," "continue," "could," "estimate," 
"expect," "intend," "may," "plan," "potential," "predict," "project," 
"should," "target," "would," and similar expressions, constitute 
forward-looking statements within the meaning of The Private Securities 
Litigation Reform Act of 1995. Actual results may differ materially from 
those indicated by such forward-looking statements as a result of 
various important factors, including: the uncertainties inherent in the 
initiation of future clinical trials, availability and timing of data 
from ongoing and future clinical trials and the results of such trials, 
whether preliminary results from a clinical trial will be predictive of 
the final results of that trial or whether results of early clinical 
trials or preclinical studies will be indicative of the results of later 
clinical trials, expectations for regulatory approvals, laws and 
regulations affecting government contracts and funding awards, 
availability of funding sufficient for the Company's foreseeable and 
unforeseeable operating expenses and capital expenditure requirements 
and other factors discussed in the "Risk Factors" section of filings 
that the Company makes with the Securities and Exchange Commission, 
including the Company's Annual Report on Form 20-F for the fiscal year 
ended 31 January 2018. Accordingly, readers should not place undue 
reliance on forward-looking statements or information. In addition, any 
forward-looking statements included in this press release represent the 
Company's views only as of the date of this release and should not be 
relied upon as representing the Company's views as of any subsequent 
date. The Company specifically disclaims any obligation to update any 
forward-looking statements included in this press release. 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

November 12, 2018 07:00 ET (12:00 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

1 Year Summit Therapeutics Chart

1 Year Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

Your Recent History

Delayed Upgrade Clock